Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Product Details
100-05-100UG
Applications
Tested Dilution
Publications
Product Specifications
Species
Human
Published species
Human
Expression System
E. coli
Amino acid sequence
MLGSFVHCEP CDEKALSMCP PSPLGCELVK EPGCGCCMTC ALAEGQSCGV YTERCAQGLR CLPRQDEEKP LHALLHGRGV CLNEKSYREQ VKIERDSREH EEPTTSEMAE ETYSPKIFRP KHTRISELKA EAVKKDRRKK LTQSKFVGGA ENTAHPRIIS APEMRQESEQ GPCRRHMEAS LQELKASPRM VPRAVYLPNC DRKGFYKRKQ CKPSRGRKRG ICWCVDKYGM KLPGMEYVDG DFQCHTFDSS NVS
Molecular weight
28.6 kDa
Class
Recombinant
Type
Protein
Purity
≥ 98% by SDS-PAGE gel and HPLC analyses.
Endotoxin concentration
<1 EU/µg
Activity
The ED50 was determined by its ability to inhibit IGF-II induced proliferation of MCF-7 is ≤ 0.3 ug/ml in the presence of 15 ng/ml of human IGF-II.
Conjugate
Form
Lyophilized
Purification
purified
Contains
no preservative
Storage conditions
-20°C
Shipping conditions
Ambient
Product Specific Information
Recombinant Human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.
This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
Target Information
The insulin-like growth factor-binding proteins, or IGFBPs, are a family of homologous proteins that have co-evolved with the IGFs. They serve not only as shuttle molecules for the soluble IGFs, but also confer a level of regulation to the IGF signaling system. Physical association of the IGFBPs with IGF influences the bio-availability of the growth factors, as well as their concentration and distribution in the extracellular environment. In addition, the IGFBPs appear to have biological activity independent of the IGFs. Seven IGFBPs have thus far been described, each differing in their tissue distribution, half-lives and modulation of IGF interactions with their receptors. For instance, IGFBP1 is negatively regulated by insulin production. The IGFBP1 gene is expressed at a high level during fetal liver development and in response to nutritional changes and diabetes. It has been suggested that IGFBP2 functions as chaperone, escorting IGFs to their target tissues. It is expressed in several human tissues including fetal eye and fetal brain. IGFBP3 is the most abundant IGFBP and is complexed with roughly 80% of the serum IGFs. Both IGFBP3 and IGFBP4 are released by dermal fibroblasts in response to incision injury. IGFBP5 is secreted by myoblasts and may play a key role in muscle differentiation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Bioinformatics
Protein Aliases: IBP 5; IBP-5; IGF BP5; IGF-binding protein 5; IGFBP; IGFBP 5; IGFBP-5; Insulin like growth factor binding protein; insulin-like growth factor binding protein 5; Insulin-like growth factor-binding protein 5
Gene Aliases: IBP5; IGFBP5
UniProt ID: (Human) P24593
Entrez Gene ID: (Human) 3488
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support